1 Restriction Practice Updates Julie Burke TC1600 Quality Assurance Specialist 571-272-0512

Slides:



Advertisements
Similar presentations
Technology Center 1600 Training on Writing Rejections Under 35 U.S.C. § 103.
Advertisements

35 U.S.C. § 112, First Paragraph By: Sheetal S. Patel.
USPTO Restriction Training Materials and Chapter 800 Revisions
Proteomics Examination Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703)
More on Restriction Practice Jim Housel SPE, Art Unit 1648 (703)
UNITED STATES PATENT AND TRADEMARK OFFICE A full transcript of this presentation can be found under the “Notes” Tab. Claim Interpretation: Broadest Reasonable.
Double Patenting Simplified
Julie Burke TC1600 QAS REJOINDER PRACTICE Julie Burke TC1600 QAS
1 35 USC 112, 1 st paragraph enablement Enablement Practice in TC 1600 Deborah Reynolds, SPE
The America Invents Act (AIA) - Rules and Implications of First to File, Prior Art, and Non-obviousness -
September 14, U.S.C. 103(c) as Amended by the Cooperative Research and Technology Enhancement (CREATE) Act (Public Law ) Enacted December.
35 U.S.C. 112, Sixth Paragraph MPEP 2181 – 2186 Jean Witz Quality Assurance Specialist Technology Center 1600.
Filing Compliant Reexam Requests Andy Kashnikow SPE, Central Reexamination Unit Andy Kashnikow SPE, Central Reexamination Unit June, 2010.
1 Principles in Restriction Practice TC 1600 Anthony Caputa TC Practice Specialist (571)
“REACH-THROUGH CLAIMS”
1 Biotechnology Partnership Meeting April 17, 2001 James Martinell Senior Level Examiner Technology Center 1600.
Determination of Obviousness Practice Under the Genus-Species Guidelines and In re Ochiai; In re Brouwer Sreeni Padmanabhan & James Wilson Supervisory.
Restriction Practice for Nucleic Acid Molecules Julie Burke QAS/PM
1 Single Nucleotide Polymorphisms (SNP) Gary Jones SPE, Technology Center 1600 (703)
Restriction Practice for Genus Claims Species Claims Linking Claims and Markush Claims Julie Burke QAS/PM TC1600.
Determining Obviousness under 35 USC 103 in view of KSR International Co. v. Teleflex TC3600 Business Methods January 2008.
by Eugene Li Summary of Part 3 – Chapters 8, 9, and 10
Patent Applications Overlapping the Biotechnology and Mechanical Arts THOMAS BARRETT
By Paul J. Lee. Disclaimer The opinions and views expressed in these materials are not necessarily those of DexCom and reflect only the personal views.
Examination Issues: Immunology Yvonne (Bonnie) Eyler Quality Assurance Specialist Technology Center 1600 USPTO (571)
1 Unity of Invention: Biotech Examples TC1600 Special Program Examiner Julie Burke (571)
RESTRICTING BETWEEN PRODUCT and PROCESS INVENTIONS Bruce Campell Supervisory Patent Examiner Art Unit
Current and Future USPTO Practice RESTRICTION PRACTICES AT THE USPTO 1 © AIPLA 2015.
December 8, Changes to Patent Fees Under the Consolidated Appropriations Act, 2005 (H.R. 4818)(upon enactment) and 35 U.S.C. 103(c) as Amended by.
Julie Burke TC1600 QAS/PM New Matter, Incorporation By Reference, Restriction and Claim Language for Nucleic Acid Molecules.
Utility Requirement in Japan Makoto Ono, Ph.D. Anderson, Mori & Tomotsune Website:
1 ANTICIPATION BY INHERENCY IN PRIOR ART James O. Wilson Supervisory Patent Examiner Technology Center 1600 USPTO (571)
Broadening the Scope of the Claims in Gene Therapy Applications Deborah Reynolds Detailee, TCPS
Notice of Proposed Rule Making Affecting Claims That Recite Alternatives 1 Robert Clarke, Director Office of Patent Legal Administration (571)
Restriction & Double Patenting Mojdeh Bahar, J.D., M.A., CLP Chief, Cancer Branch Office of Technology Transfer National Institutes of Health U.S. Department.
1 Patent Law in the Age of IoT The Landscape Has Shifted. Are You Prepared? 1 Jeffrey A. Miller, Esq.
Like.com vs. Ugmode Prosecution history of patent *** CONFIDENTIAL *** Prepared by Ugmode, Inc.
U.S. Patent and Trademark Office Technology Center 1600 Michael P. Woodward Unity of Invention: Biotech Examples.
To Restrict or Not To Restrict That Is The Question? Divided We Stand! Or Undivided We Stand!! By Joseph K. McKane SPE, Art Unit 1626.
3/2/091 PCT Unity of Invention with Pharmaceutical and Chemical Examples Julie Burke TC1600 Quality Assurance Specialist
July 18, U.S.C. 103(c) as Amended by the Cooperative Research and Technology Enhancement (CREATE) Act (Public Law ) Enacted December 10,
Post-Grant & Inter Partes Review Procedures Presented to AIPPI, Italy February 10, 2012 By Joerg-Uwe Szipl Griffin & Szipl, P.C.
Election of Species Joseph K. McKane SPE, Art Unit 1626 April 27, 2004.
1 Written Description Analysis and Capon v. Eshhar Jeffrey Siew Supervisory Patent Examiner AU 1645 USPTO (571)
1 When is it NOT Appropriate to Restrict? Julie Burke TC1600 QAS
Patentability Considerations in the 3-D Structure Arts Patentability Considerations in the 3-D Structure Arts Michael P. Woodward Supervisory Patent Examiner.
3 rd Party Participation Bennett Celsa TC 1600 QAS.
Examining Claims for Compliance with 35 U.S.C. 112(a): Part II – Enablement Focus on Electrical/Mechanical and Computer/Software-related Claims August.
Claims and Continuations Final Rule 1 Joni Y. Chang Senior Legal Advisor Office of Patent Legal Administration (571) ,
FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice Julie Burke TC1600 Quality Assurance Specialist
UNITED STATES PATENT AND TRADEMARK OFFICE
Restriction Practice for Combinations and Subcombinations
Vector Claims in Gene Therapy Applications: In vivo vs. In vitro Utilities Deborah Reynolds SPE GAU
1 Restriction Petition Survey; A Few Helpful Hints Julie Burke TC1600 Special Program Examiner
James Toupin – General Counsel February 1, Summary of Proposed Rule Changes to Continuations, Double Patenting, and Claims.
Biotechnology/Chemical/Pharmaceutical Customer Partnership Topic: Biotechnology/Chemical/Pharmaceutical Customer Partnership Topic: Biological Deposits.
Claims Proposed Rulemaking Main Purposes É Applicant Assistance to Improve Focus of Examination n Narrow scope of initial examination so the examiner is.
How to Claim your Biotech- Based Invention Deborah Reynolds Detailee, TCPS
Examination Practice in Applications Presenting “Reach-Through Claims” George Elliott Practice Specialist Technology Center 1600
Double Patenting Deborah Reynolds SPE Art Unit 1632 Detailee, TC1600 Practice Specialist
(c) 2004, David Schnapf, Sheppard Mullin Richter & Hampton LLP 1 Examiner Use of Background Statements David Schnapf Sheppard Mullin Richter & Hampton.
 An important first quality of any good thesis is that it should stem from real problems in the field. Therefore, a researcher should emphasize the reasons.
1 FY08 Restriction Petition Update and Burden Julie Burke Quality Assurance Specialist Technology Center 1600.
PATENT OFFICE PROSECUTION
Preparing a Patent Application
Claims and Continuations Final Rule
Ram R. Shukla, Ph.D. SPE AU 1632 & 1634 Technology Center
Preparing a Patent Application
Examination Practice in Applications Presenting “Reach-Through Claims”
Examination Issues: Immunology
Presentation transcript:

1 Restriction Practice Updates Julie Burke TC1600 Quality Assurance Specialist

2 Contents Form Paragraph (FP) Changes published 21 January –Applies to US applications only Reasons for Burden now required in FPs 8.01, 8.02 and 8.21 Election of Species requirements –FP 8.01 when species claims are present –FP 8.02 generic claims only Reconsideration and Finality of a Restriction Requirement –for both U.S. applications under 35 U.S.C. 111(a) and U.S. national stage entries under 35 U.S.C. 371.

3 Restriction Form Paragraph Changes Memo dated 1/21/10 Memorandum Entitled “Changes to Restriction Form Paragraphs” published on 1/21/10. FPs 8.01, 8.02, and 8.22 currently in MPEP 800 (8 th Edition, rev. 7, July 2008), correspond to changed FPs 8.01, 8.02 and 8.21 in 1/21/10 Memo and Office action Correspondence Subsystem (OACS).

4 Do the FPs apply to Instant Application? Yes, if the application is filed under 35 U.S.C. 111(a), and plural inventions under 35 U.S.C. 121 are claimed. Note: The claims of the application must be compared to determine if they describe plural independent or distinct inventions. MPEP No, if application is filed in the National stage under 35 U.S.C. 371 and plural inventions are claimed. the application is filed in the National stage under 35 U.S.C. 371 and plural inventions are claimed. PCT unity of invention standards must be used. PCT unity of invention standards must be used. See MPEP Chapter 1800 for details. See MPEP Chapter 1800 for details.

5 Confusion over the 4/25/07 Restriction Form Paragraphs The 1/21/10 memo supersedes the 4/25/07 memo and addresses confusion over (1) Whether applicant must always elect a single species? (2) Why the species are independent or distinct? (3) Why there would be a burden if election of species were not required?

6 MPEP 803 Requires the Examiner to Provide Reasons “Examiners must provide reasons and/or examples to support conclusions, but need not cite documents to support the restriction requirement in most cases.” MPEP 803

7 MPEP 808 Requires the Examiner to Provide Reasons “The particular reasons relied on by the examiner for holding that the inventions as claimed are either independent or distinct should be concisely stated. A mere statement of conclusion is inadequate. The reasons upon which the conclusion is based should be given.” MPEP 808

8 Burden Discussed in 1/21/10 Memo “As noted in MPEP 803 and , if the examination and search of all the claims in an application can be made without serious burden, restriction should not be required, even though they are drawn to independent or distinct inventions, including species.” 1/21/10 memo

9 Burden Discussed in MPEP 803 “If the search and examination of all the claims in an application can be made without serious burden, the examiner must examine them on the merits, even though they include claims to independent or distinct inventions.” MPEP 803

10 Prima Facie Showing of Burden Discussed in MPEP 803 “For purposes of the initial requirement, a serious burden on the examiner may be prima facie shown by appropriate explanation of separate classification, or separate status in the art, or a different field of search as defined in MPEP § That prima facie showing may be rebutted by appropriate showings or evidence by the applicant.” MPEP 803

11 Burden Discussed in MPEP “If the members of the Markush group are sufficiently few in number or so closely related that a search and examination of the entire claim can be made without serious burden, the examiner must examine all the members of the Markush group in the claim on the merits, even though they may be directed to independent and distinct inventions. In such a case, the examiner will not follow the procedure described below and will not require provisional election of a single species. See MPEP § ” MPEP

12 Burden Discussed in MPEP “Where, however, the classification is the same and the field of search is the same and there is no clear indication of separate future classification and field of search, no reasons exist for dividing among independent or related inventions.” MPEP

13 Examiners are Now Required to Specify a Reason for Burden in FPs 8.01, 8.02 and 8.21 “To help ensure that all restriction requirements, including election of species requirement, set forth the requisite burden, and to give applicants notice of why there is burden, form paragraphs 8.01, 8.02 and 8.21 have been revised to provide for the examiner to specify at least one applicable reason. Possible applicable reason are listed in the examiner notes to the form paragraphs, and are consistent with MPEP ” 1/21/10 Memo

14 Changes to Form Paragraph 8.21: To Establish Burden AND Requirement for Election and Means for Traversal for all Restrictions, other than an Election of Species The examiner is required to provide reasons for burden. “Restriction for examination purposes as indicated is proper because all these inventions listed in this action are independent or distinct for the reasons given above and there would be a serious search and/or examination burden if restriction were not required because at least the following reason(s) apply: [1].” Memo 1/21/10

15 Three Examples of Reasons to Establish Prima Facie Showing for Burden “In bracket 1 insert the applicable reason(s) why there is search and/or examination burden: --the inventions have acquired a separate status in the art in view of their different classification --the inventions have acquired a separate status in the art in view of their recognized divergent subject matter --the inventions require a different field of search (e.g., searching different classes/subclasses or electronic resources or employing different search strategies or search queries.)” MPEP and Examiner Note 2 of FP 8.21 dated 1/21/10

16 First Example of a Reason to Establish Prima Facie Showing for Burden (A) Separate classification thereof : This shows that each invention has attained recognition in the art as a separate subject for inventive effort, and also a separate field of search. Patents need not be cited to show separate classification. MPEP

17 Second Example of a Reason to Establish Prima Facie Showing for Burden (B) A separate status in the art when they are classifiable together: Even though they are classified together, each invention can be shown to have formed a separate subject for inventive effort when the examiner can show a recognition of separate inventive effort by inventors. Separate status in the art may be shown by citing patents which are evidence of such separate status, and also of a separate field of search. MPEP

18 Third Example of a Reason to Establish Prima Facie Showing for Burden (C) A different field of search: Where it is necessary to search for one of the inventions in a manner that is not likely to result in finding art pertinent to the other invention(s) (e.g., searching different classes /subclasses or electronic resources, or employing different search queries, a different field of search is shown, even though the two are classified together. The indicated different field of search must in fact be pertinent to the type of subject matter covered by the claims. Patents need not be cited to show different fields of search. MPEP

19 Two Form Paragraphs to Require an Election of Species in US Applications “An examiner should set forth a requirement for election of a single disclosed species in a Markush-type claim –using form paragraph 8.01 when claims limited to species are present or –using form paragraph 8.02 when no species claims are present. See MPEP § (a) and § (a).” MPEP

20 Example of Single Species Claims; FP 8.01 Claim 1. A composition comprising Compound X. Claim 2. A composition comprising Compound Y. Claim 3. A composition comprising Compound Z. Claims 1, 2 and 3 are each limited to single species of compound X, Y or Z. The specification teaches that compounds X, Y and Z are all pain relievers. Because single species claims are present in this claim set, if an election of species requirement is warranted, the examiner should use FP 8.01.

21 Example of a claim set which contains only generic claims; species are disclosed; FP 8.02 (Generic) Claim 1. A composition comprising a pain reliever. (Markush) Claim 2. A composition comprising a pain reliever selected from the group consisting Compound X, Compound Y or Compound Z. Claims 1 and 2 are both generic to more than one species of citrus fruit. When either claims 1 or 2 are present in a claim set that lacks any single species claims, if an election of species requirement is warranted, the examiner should use FP 8.02.

22 Example of a claim set which includes both species and generic claims; FP 8.01 (Generic) Claim 1. A composition comprising a pain reliever. (Markush) Claim 2. A composition comprising a pain reliever selected from the group consisting Compound X, Compound Y or Compound Z. Claim 1. A composition comprising Compound X. Claim 2. A composition comprising Compound Y. Claim 3. A composition comprising Compound Z. When both generic and species claims are present, if an election of species requirement is warranted, the examiner should use FP This holds true regardless of the presence of generic claim 1 or Markush claim 2. This also applies regardless of the independent or dependent format of the species claims.

23 Changes to Form Paragraph 8.01: Requiring an Election of Species; Species Claim(s) Present The examiner is required to provide reasons for independence, distinction and burden. “The species are independent or distinct because [2].” “There is a search and/or examination burden for the patentably distinct species as set forth above because at least the following reason(s) apply: [4].” Applicant is required to elect “a species or a group of patentably indistinct species.” Memo 1/21/10

24 Changes to Form Paragraph 8.02: Requiring an Election of Species; No Species Claim Present The examiner is required to provide reasons for independence, distinction and burden. “The species are independent or distinct because [3].” “There is a search and/or examination burden for the patentably distinct species as set forth above because at least the following reason(s) apply: [4].” Applicant is required to elect “a species or a group of patentably indistinct species.” Memo 1/21/10

25 37 CFR 1.146: Election of Species “In the first action on an application containing a generic claim to a generic invention (genus) and claims to more than one patentably distinct species embraced thereby, the examiner may require the applicant in the reply to that action to elect a species of his or her invention to which his or her claim will be restricted if no claim to the genus is found to be allowable. However, if such application contains claims directed to more than a reasonable number of species, the examiner may require restriction of the claims to not more than a reasonable number of species before taking further action in the application.” 37 CFR

26 Restriction Between Mutually Exclusive Species “Where two or more species are claimed, a requirement for restriction to a single species may be proper if the species are mutually exclusive. Claims to different species are mutually exclusive if one claim recites limitations disclosed for a first species but not a second, while a second claim recites limitations disclosed only for the second species and not the first. This may also be expressed by saying that to require restriction between claims limited to species, the claims must not overlap in scope.” (f)

27 What does “Mutually Exclusive” Mean? Claims to different species are mutually exclusive if one claim recites limitations disclosed for a first species but not a second, while a second claim recites limitations disclosed only for the second species and not the first. MPEP (f) This may also be expressed by saying that to require restriction between claims limited to species, the claims must not overlap in scope. MPEP (f)

28 Three Types of “Species” which are Not Considered Patentably Distinct Where the “species” are identical. –the scope of the first and second “species” is identical. Where the “species” overlap in scope. –an embodiment within one “species” anticipates an embodiment in a second “species” Where the species are distinct, (neither anticipates the other) but would be obvious over each other in view of 35 USC 103.

29 Example: “Species” are not patentably distinct because their scope is identical Claim 1. A compound of formula I given by Claim 1. A compound of formula I given by Claim 2. The compound 6-chloro-4-(3-aminopropoxy)-1-benzopyran-2-one. Claim 3. The chromane compound of formula I. Claims 1, 2 and 3 are not distinct from each other as the claims merely define the same essential characteristics of a single disclosed embodiments of an invention. Practice Tip: If an examiner requires an election between the “Species” of Claims 1, 2 and 3, Applicant may wish to elect the “group of species of claims 1, 2 and 3” and traverse such a requirement using MPEP , (f) and (h).

30 Example: “Species” are not patentably distinct because the claims describe a single disclosed embodiment Claim 1. A compound of formula 1. Claim 2. A compound having the x-ray diffraction pattern as depicted in Fig 12. The specification discloses a compound of formula 1 having an x-ray diffraction pattern depicted in Figure 12. Claim 1 is not distinct from claim 2 as both claims merely define the same essential characteristics of a single disclosed embodiment of an invention. Do not confuse claim limitations with required characteristics. Claims are read in light of specification, but do not read limitations from specification into claims. Practice Tip: If an examiner requires an election between the “Species” of Claims 1 and 2, Applicant may wish to elect the group of “species” of claims 1 and 2 and traverse the requirement to elect a single species using MPEP , (f) and (h).

31 Example: “Species” not distinct as claimed when the claims vary in breath or scope of definition. Claim 1. An isolated nucleic acid molecule having SEQ ID No 1. Claim 2. A vector comprising the nucleic acid molecule of claim 1. Claim 3. A host cell comprising the vector of claim 2. Claims 1, 2 and 3 are not distinct because claims 1, 2 and 3 vary in breadth or scope of definition. claim 1 encompass (overlaps in scope with) claim 2. claim 2 encompass (overlaps in scope with) claim 3. claim 3 is encompassed by both claims 1 and 2. Practice Tip: If an examiner requires an election between the “Species” of Claims 1 and 2, Applicant may wish to elect the group of “species” of Claims 1, 2 and 3 and traverse the requirement to elect a single species using MPEP , (f) and (h).

32 Example: “Species” not distinct as claimed because the claims vary in breath or scope of definition. Claim 1. A composition comprising an active agent selected from the group consisting of a protein, a cytokine, an interleukin, a leukocytotrophic hormone, IL-2, or a protein consisting of SEQ ID No 1. The specification discloses that the amino acid sequence of IL-2 is SEQ ID No 1. IL-2 is an interleukin protein, which is a specific type of cytokine and functions as a leukocytotrophic hormone. For this reason, the “Species” recited in Claim 1 are not distinct because they vary in breadth or scope of definition. Practice Tip: If an examiner requires an election between the “Species” recited in the alternative of Claim 1, upon election, Applicant may wish to traverse using MPEP , (f) and (h).

33 Example: Treatment of “Species” which are Obvious over Each Other Distinctness between related inventions requires that at least one invention would not have been obvious over the other (i.e., that the inventions are not obvious variants). If the claims on their face are obvious over each other, restriction is not proper. For example of obvious variants, the application claims a method of connecting two parts together. In one embodiment, the method requires a screw. In a second embodiment, the method requires a nail. The examiner should group together embodiments considered clearly unpatentable over each other; see MPEP (h).

34 The examiner should group together species considered unpatentable over each other. “Election of species should not be required between claimed species that are considered clearly unpatentable (obvious) over each other. In making a requirement for restriction in an application claiming plural species, the examiner should group together species considered clearly unpatentable over each other.” MPEP (a) Emphasis in original.

35 Traversal on the Grounds that the Species are Obvious Variants over Each Other. “Should applicant traverse on the ground that the species, or groupings of patentably indistinct species from which election is required, are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing them to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the species unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other species.” 1/21/10 Memo

36 An Expressed Admission of Obviousness “If there is an express admission that the claimed inventions would have been obvious over each other within the meaning of 35 U.S.C. 103, restriction should not be required. In re Lee, 199 USPQ 108 (Comm’r Pat. 1978). MPEP 803

37 Implications of an Expressed Admission of Obviousness Claim 1. A method of attaching Part A to Part B using a nail. Claim 2. A method of attaching Part A to Part B using a screw. Claim 1 and Claim 2 are distinct because the method of using a nail does not anticipate using a method of using a screw and vice versa. However, if applicants make the admission that claims 1 and 2 would be obvious over each other in view of 35 USC 103, and if the examiner found prior art (Church) teaching a method of fixing part A to Part B using a nail, the examiner may set forth an obviousness rejection of claim 2 under 35 USC 103 over the Church reference in view of applicants admission.

38 Traversal and Reconsideration in view of the Claims as Currently Amended. 37 CFR Reconsideration of requirement. If the applicant disagrees with the requirement for restriction, he may request reconsideration and withdrawal or modification of the requirement, giving the reasons therefor. (See § 1.111). 37 CFR 1.111(c) In amending in reply to a rejection of claims in an application or patent under reexamination, the applicant or patent owner must clearly point out the patentable novelty which he or she thinks the claims present in view of the state of the art disclosed by the references cited or the objections made. The applicant or patent owner must also show how the amendments avoid such references or objections.

39 Traversal and Reconsideration of a Restriction Requirement Combination/Subcombination “If the combination claims are amended after a restriction requirement such that each combination, as claimed, requires all the limitations of the subcombination as claimed, i.e., if the evidence claim ABbr is deleted or amended to require Bsp, the restriction requirement between the combination and subcombination should not be maintained. MPEP (c).” Subcombinations Useable Together: “If applicant proves or provides an argument, supported by facts, that the other use, suggested by the examiner, cannot be accomplished or is not reasonable, the burden is on the examiner to document a viable alternative use or withdraw the requirement.” MPEP (d).

40 Traversal and Reconsideration of a Restriction Requirement Process and Apparatus “If applicant proves or provides convincing argument that there is no material difference or that a process cannot be performed by hand (if examiner so argued), the burden is on the examiner to document another materially different process or apparatus or withdraw the requirement.” MPEP (e) Process of making and product made: “If applicant convincingly traverses the requirement, the burden shifts to the examiner to document a viable alternative process or product, or withdraw the requirement.” MPEP (f)

41 Traversal and Reconsideration of a Restriction Requirement Apparatus and Product Made “If applicant either proves or provides convincing argument that the alternative example suggested by the examiner is not workable, the burden is on the examiner to suggest another viable example or withdraw the restriction requirement. MPEP (g) Product and Process of Using: “If the applicant either proves or provides a convincing argument that the alternative use suggested by the examiner cannot be accomplished, the burden is on the examiner to support a viable alternative use or withdraw the requirement. MPEP (h)

42 Making a Restriction Requirement FINAL “Where the initial requirement is traversed, it should be reconsidered. If, upon reconsideration, the examiner is still of the opinion that restriction is proper, it should be repeated and made final in the next Office action. (See MPEP § , emphasis added.) In doing so, the examiner should reply to the reasons or arguments advanced by applicant in the traverse.” MPEP

43 Questions? Julie Burke TC1600 Quality Assurance Specialist